MX2016014384A - Apremilast for the treatment of a liver disease or a liver function abnormality. - Google Patents

Apremilast for the treatment of a liver disease or a liver function abnormality.

Info

Publication number
MX2016014384A
MX2016014384A MX2016014384A MX2016014384A MX2016014384A MX 2016014384 A MX2016014384 A MX 2016014384A MX 2016014384 A MX2016014384 A MX 2016014384A MX 2016014384 A MX2016014384 A MX 2016014384A MX 2016014384 A MX2016014384 A MX 2016014384A
Authority
MX
Mexico
Prior art keywords
apremilast
liver
treatment
function abnormality
liver disease
Prior art date
Application number
MX2016014384A
Other languages
Spanish (es)
Inventor
Stevens Randall
HOUGH Douglas
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2016014384A publication Critical patent/MX2016014384A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

Methods of treating, managing or preventing liver disease are disclosed. Specific methods encompass the administration of apremilast, alone or in combination with additional active agents or treatment regimens.
MX2016014384A 2014-06-23 2015-06-22 Apremilast for the treatment of a liver disease or a liver function abnormality. MX2016014384A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462016013P 2014-06-23 2014-06-23
PCT/US2015/036898 WO2015200177A1 (en) 2014-06-23 2015-06-22 Apremilast for the treatment of a liver disease or a liver function abnormality

Publications (1)

Publication Number Publication Date
MX2016014384A true MX2016014384A (en) 2017-01-20

Family

ID=53674276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014384A MX2016014384A (en) 2014-06-23 2015-06-22 Apremilast for the treatment of a liver disease or a liver function abnormality.

Country Status (6)

Country Link
US (1) US10300042B2 (en)
EP (1) EP3157520B1 (en)
JP (1) JP6687550B2 (en)
ES (1) ES2749433T3 (en)
MX (1) MX2016014384A (en)
WO (1) WO2015200177A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017317575B2 (en) * 2016-08-26 2021-10-14 Takeda Pharmaceutical Company Limited Treatment of nonalcoholic fatty liver disease
WO2018069422A1 (en) * 2016-10-12 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of non-alcoholic fatty liver disease
IL287665A (en) * 2019-04-30 2022-07-01 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
WO2022182895A1 (en) * 2021-02-26 2022-09-01 Rutgers, The State University Of New Jersey Compounds and methods for treating congenital erythropoietic porphyria
CN117597106A (en) * 2021-05-28 2024-02-23 美国安进公司 Apremilast formulation

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
US3322755A (en) 1964-03-10 1967-05-30 Boehringer Sohn Ingelheim Basic-substituted 1, 2, 3, 4-tetrahydropyrimido [5, 4-d]-pyrimidines
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
DE2051871A1 (en) 1969-05-16 1971-11-18 The Wellcome Foundation Ltd., London Beta-amino-alpha-aryloxymethylacrylonitrile - and 2,4-diamino-5-benzylpyrimidine derivs. useful as antibacterial agents
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS4966691A (en) 1972-10-30 1974-06-27
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4162316A (en) 1975-03-12 1979-07-24 Dainippon Pharmaceutical Co., Ltd. 1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives and compositions containing the same
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
US4001237A (en) 1976-02-18 1977-01-04 Bristol-Myers Company Oxazole, isoxazole, thiazole and isothiazole amides
US4001238A (en) 1976-02-18 1977-01-04 Bristol-Myers Company 1,3,4-oxadiazole amides
US4047404A (en) 1976-11-17 1977-09-13 Tanno Senshoku Kogyo Co., Ltd. Printed fabric washing apparatus
US4101548A (en) 1977-02-22 1978-07-18 Bristol-Myers Company 1,2,3-Thiadiazole amides
US4209623A (en) 1978-06-07 1980-06-24 Bristol-Myers Company Pyrimidine-5-N-(1H-tetrazol-5-yl)-carboxamides
GB2063249A (en) 1979-10-09 1981-06-03 Mitsubishi Yuka Pharma 4-Phenylphthalazine derivatives
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DE3770095D1 (en) 1986-08-21 1991-06-20 Pfizer CHINAZOLINDIONE AND PYRIDOPYRIMIDINDIONE.
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
DE68908786T2 (en) 1988-06-16 1994-03-17 Smith Kline French Lab Condensed pyrimidine derivatives, processes and intermediates for their preparation and pharmaceutical preparations containing them.
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
GB8909560D0 (en) 1989-04-26 1989-06-14 Smith Kline French Lab Chemical compounds
GB8923131D0 (en) 1989-10-13 1989-11-29 Smith Kline French Lab Chemical compounds
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5401774A (en) 1991-03-08 1995-03-28 University Of Arizona Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
PT100905A (en) 1991-09-30 1994-02-28 Eisai Co Ltd BICYCLE HYGIENEOUS HETEROCYCLIC COMPOUNDS CONTAINING BENZENE, CYCLOHEXAN OR PYRIDINE AND PYRIMIDINE, PYRIDINE OR IMIDAZOLE SUBSTITUTES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5354571A (en) 1992-04-27 1994-10-11 Rheon Automatic Machinery Co., Ltd. Method for aligning and bending individual round elongated dough pieces
US5243826A (en) 1992-07-01 1993-09-14 Apd Cryogenics Inc. Method and apparatus for collecting liquid cryogen
JP2657760B2 (en) 1992-07-15 1997-09-24 小野薬品工業株式会社 4-aminoquinazoline derivatives and pharmaceuticals containing them
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5614627A (en) 1993-09-10 1997-03-25 Eisai Co., Ltd. Quinazoline compounds
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US5608914A (en) 1994-11-21 1997-03-11 Keesler; Daren Headcover
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5703098A (en) 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
DE19501481A1 (en) 1995-01-19 1996-07-25 Bayer Ag 2,8-disubstituted quinazolinones
DE19501482A1 (en) 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituted purine-6-ones
DE19501480A1 (en) 1995-01-19 1996-07-25 Bayer Ag 9-substituted 2- (2-n-alkoxyphenyl) -purin-6-one
US5614530A (en) 1995-03-10 1997-03-25 Sterling Winthrop Inc. Substituted N-arylmethyl and heterocyclmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines and compositions and methods of use thereof
US5488055A (en) 1995-03-10 1996-01-30 Sanofi Winthrop Inc. Substituted N-cycloalkylmethyl-1H-pyrazolo(3,4-b)quinolin-4 amines and compositions and methods of use thereof
ATE219765T1 (en) 1995-04-10 2002-07-15 Fujisawa Pharmaceutical Co INDOLE DERIVATIVES AS CGMP-PDE INHIBITORS
TW381092B (en) 1995-07-07 2000-02-01 Otsuka Pharma Co Ltd Novel benzimidazole derivatives for use in treating arteriosclerotic diseases
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5658940A (en) 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US5710170A (en) 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9526243D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
EP0882718B1 (en) 1995-12-28 2005-08-31 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
DE19632423A1 (en) 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidines
WO1998008848A1 (en) 1996-08-30 1998-03-05 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
DE69717867T2 (en) 1996-10-04 2003-10-02 Kyorin Seiyaku Kk PYRAZOLOPYRIDYLPYRAZINONE DERIVATIVES AND A METHOD FOR THE PRODUCTION THEREOF
DE19642451A1 (en) 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophene carboxamides
DE19644228A1 (en) 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidines
KR100239800B1 (en) 1996-11-28 2000-03-02 손경식 4,5-diaminopyrimidine derivatives and its preparation
WO1998038168A1 (en) 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
ES2302350T3 (en) 1997-02-28 2008-07-01 Nycomed Gmbh SYNERGIC COMBINATION OF PDE INHIBITORS AND ADENYLATOCICLASS AGONISTS OR GUANILILCICLASA AGONISTS.
CN1265590A (en) 1997-07-31 2000-09-06 赛尔金有限公司 Substituted alkanohydroxamic acid and method of reducing TNF 'alpha' levels
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
US6034089A (en) 1997-10-03 2000-03-07 Merck & Co., Inc. Aryl thiophene derivatives as PDE IV inhibitors
AU751453C (en) 1997-11-25 2003-04-10 Warner-Lambert Company Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
CA2364653A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
US6316472B1 (en) 1999-05-13 2001-11-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6667316B1 (en) 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
PT1244649E (en) 1999-12-23 2005-06-30 Icos Corp PHOSPHODIESTERASE INHIBITORS SPECIFIC MFA CYCLIC
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) * 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
KR20140142323A (en) * 2008-03-27 2014-12-11 셀진 코포레이션 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CA2736171A1 (en) 2008-09-10 2010-03-18 Celgene Corporation Processes for the preparation of aminosulfone compounds
ME01883B (en) 2009-06-18 2014-12-20 Concert Pharmaceuticals Inc Deuterated i soindoline- i, 3-dione derivatives as pde4 and tnf-alpha inhibitors
CN102781443A (en) 2009-11-19 2012-11-14 细胞基因公司 Apremilast For The Treatment Of Sarcoidosis
CN104761484B (en) 2014-11-24 2018-03-27 上海优拓医药科技有限公司 A kind of A Pusite crystal formations II without solvate of stabilization and preparation method thereof

Also Published As

Publication number Publication date
US10300042B2 (en) 2019-05-28
WO2015200177A1 (en) 2015-12-30
EP3157520A1 (en) 2017-04-26
EP3157520B1 (en) 2019-09-04
JP2017526628A (en) 2017-09-14
US20170143671A1 (en) 2017-05-25
JP6687550B2 (en) 2020-04-22
ES2749433T3 (en) 2020-03-20

Similar Documents

Publication Publication Date Title
MX2015008685A (en) Treatment of psoriatic arthritis using apremilast.
PL3554631T3 (en) Treating patients with ttfields with the electrode positions optimized using deformable templates
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2018002723A (en) Peptidomimetic macrocycles and uses thereof.
IL249370A0 (en) Fap-activated therapeutic agents, and uses related thereto
UY36307A (en) COMBINED THERAPIES FOR CANCER TREATMENT
TW201613887A (en) Antiproliferative compounds and methods of use thereof
NZ730809A (en) Methods for treating filoviridae virus infections
MY187540A (en) Compounds active towards bromodomains
HRP20190194T1 (en) 17a,21-diesters of cortexolone for use in the treatment of tumors
MX2019004500A (en) Combination therapy for c3 inhibition.
MX2015011428A (en) Methods of treating and preventing cancer drug resistance.
MX2018000778A (en) Methods for treating hepcidin-mediated disorders.
MX2016014384A (en) Apremilast for the treatment of a liver disease or a liver function abnormality.
MX2017002489A (en) Human therapeutic agents.
GB201512733D0 (en) Therapeutic agents for treating conditions associated with elevated GDF15
MY186475A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2016015568A (en) Nucleoside derivatives for the treatment of cancer.
PH12020550185A1 (en) Semaglutide in medical therapy
MX2015012043A (en) Muscarinic agonists.
PH12017500071A1 (en) Therapeutic agent for keratoconjunctive disorder
EP3538888A4 (en) Combination therapies for treating bipolar disorder, and methods for using the same
Printz Targeted therapy pretreatment helps chemotherapy for aggressive lymphoma.
UA115417U (en) METHOD OF PREVENTION AND TREATMENT OF HYPOXIC CHANGES IN CARBOPERITONEUM
TH1501007436A (en) A combination of imidazopyridazine derivatives and splitting agents for the treatment of cancer.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: AMGEN (EUROPE) GMBH